Phase I Trial of Post Allogeneic Stem Cell Transplant Maintenance Lenalidomide in Patients with High Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

Background: Patients (pts) with High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) often proceed to allogeneic hematopoietic stem cell transplant (alloHSCT) due to poorer outcomes. This is the only chance of cure; however, relapse rates after alloHSCT remain high and range between 25-50%. Maintenance approaches post-HSCT, such as hypomethylating agents or tyrosine kinase inhibitors, have been used to decrease the relapse rate with mixed results. Lenalidomide is known to augment T/NK cell activity/proliferation which lead us to hypothesize that it will enhance the Graft-versus-Leukemia (GvL) effect without increasing the incidence of acute Graft-versus-Host (GvH).

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Rajeev Krishnan, Avan Lo, Joseph Tuscano, Carol Richman, Mehrdad Abedi Source Type: research